Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Treatment before first ipilimumab treatment</td><td class="align_center">Number of cases (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Chemotherapy</td><td class="align_center">15 (68)</td></tr><tr><td class="align_left">Interleukin-2</td><td class="align_center">4 (18)</td></tr><tr><td class="align_left">Biochemotherapy</td><td class="align_center">3 (14)</td></tr><tr><td class="align_left">Other</td><td class="align_center">3 (14)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>Some patients received more than one treatment.<br/></div></td></tr></table>

Journal of Skin Cancer

tab4

Table 4

Table 4: Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma 